BrandBuild fuses comprehensive pharmaceutical commercialization experience, local know-how, an extensive partner/alliance network and a team of seasoned pharmaceutical experts to deliver exceptional solutions, service and business results.

Our team’s experience includes helping such companies as:

AstraZeneca Canada

  • Instrumental in planning and leading the highly successful Canadian launch of megabrand Symbicort to realize the company’s most successful product uptake in category history.
  • Planned and implemented effective KOL development initiatives, including clinical training, peer-to-peer functions, lunch-and-learn programs and a 100-person scientific advisory meeting in Arizona.
  • Achieved 80% awareness and 90% intent to prescribe across all specialties in 3 months.
  • Captured 30% NRx share within 8 weeks of launch and outpaced the growth of the market leader after only 4 months.

Iroko Pharmaceuticals Inc.

  • Led the Canadian launch and assumed Canadian commercial responsibility for a US-based pharmaceutical company operating virtually.
  • Oversaw all aspects of company operations and the branding of two product entries (Vancocin), including pricing, sales and marketing.
  • Led KOL development, hospital contracting process, buying group sales and collaboration with trade and regulatory partners.
  • Delivered a 22% increase in top line sales of a mature, non-promoted brand in 18 months.
  • Optimized price ahead of Loss of Exclusivity (LOE).
  • Directed reimbursement and hospital formulary submissions while achieving “Exceptional status” listing in Ontario.

Client: Concordia Healthcare Corp.

  • Oversaw all of the company’s commercial functions in the US including sales, business development, market/channel development marketing, brand strategy, pricing and life cycle optimization of three acquired legacy products with peak sales of $100M+ usd;
  • Managed all service partners (including marketing services vendors and the original portfolio vendors) to successfully migrate three product portfolio to the US business.
  • Established outline of corporate policies to ensure compliance with state/federal reporting and appropriate transparency.
  • Developed market expansion and launch plans for legacy products in Canada.
  • Worked with trade and manufacturers to identify improved profitability and margins on mature assets.

Oryx Pharmaceuticals Inc.

  • From startup, planned and directed the launch of a specialty pharmaceutical company and two products that generated approximately $10M in sales.
  • Conducted a detailed analysis of numerous product for in-licensing in the Canadian Specialty pharmaceutical market.
  • Led the redesign of sales organization of specialty Canadian pharmaceutical company that commercialized prescription and hospital products through purchasing, licensing and development with a focus in the cardiovascular, central nervous system (CNS) disorders, pain and infectious disease therapeutic areas.
  • Used contemporary software and developed high portfolio-specific criteria for improved territory alignment and sales force allocation.
  • Developed strategic recommendations that decreased annual sales costs by 15%.

Manna X Corporation

  • Provided interim GM leadership for the manufacturer of Advantage+ dietary supplements for immune support and athletic performance.
  • Developed the company’s business plan and selling model and helped to secure investment.
  • Built Canadian distribution and optimized supply relationships.
  • Led market segmentation, planned line extensions and established improved processes across core business functions.

Alden Connectiv Inc.

  • Launched an innovative proprietary web key technology serving healthcare and additional sectors.
  • Planned and led North American business development and marketing strategies for a company that combines digital and print media to optimize reach and drive trial/adoption of healthcare solutions through improved access to digital resources.